GA-ASI Awarded FMS Development Contract for MQ-9B PROTECTOR
General Atomics Aeronautical Systems, Inc. (GA-ASI) is pleased to announce the recent award of a $81M Foreign Military Sales contract by the US Air Force Life Cycle Management Center for the United Kingdom (UK) MQ-9B PROTECTOR unmanned aircraft system programme. This contract provides for integration and component level testing for UK specific enhancements to support the MQ-9B PROTECTOR programme. GA-ASI performed the first flight of the MQ-9B configuration less than two years ago, and the Remotely Piloted Aircraft (RPA) has continued to meet a series of key qualification milestones.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180408005029/en/
MQ-9B is the “Certifiable” (STANAG 4671) version of GA-ASI’s MQ-9 Predator® B product line. It can meet the stringent airworthiness certification requirements of various military and civil authorities, including the UK Military Airworthiness Authority (MAA) and the US FAA. (Photo: Business Wire)
MQ-9B is the “Certifiable” (STANAG 4671) version of GA-ASI’s MQ-9 Predator® B product line. Its development is the result of a five-year, company-funded effort to deliver a RPA that can meet the stringent airworthiness certification requirements of various military and civil authorities, including the UK Military Airworthiness Authority (MAA) and the US FAA. MQ-9B is the latest evolution of the multi-mission Predator B fleet. GA-ASI named its baseline MQ-9B SkyGuardian™, and the maritime surveillance variant, SeaGuardian.
“MQ-9B represents the next generation of RPA system capabilities,” said Linden Blue, CEO, GA-ASI. “It has demonstrated new airborne endurance records (>48 hours) and automatic takeoffs and landings under SATCOM-only control. MQ-9B will also have our currently operational MQ-9 detect and avoid system (with collision-avoidance radar), which will support MQ-9B operations in civil airspace.”
Other important MQ-9B milestones were achieved in 2017, including the first FAA-approved flight for a company-owned RPA through non-segregated airspace without a “chase aircraft,” when the RPA flew from Yuma, Arizona to Gray Butte, California in August 2017.
Upcoming aircraft qualification milestones include lightning protection tests, which are expected within the next 60 days. The aircraft system’s overall qualification schedule remains on track.
A weaponized variant of the system is being acquired by the Royal Air Force (RAF) under the UK’s MQ-9B PROTECTOR programme. The MQ-9B PROTECTOR will fly in excess of 40 hours with airspeeds up to 210 knots, reach altitudes of more than 40,000 feet, and carry 4750lbs (2159 kg) of external payload.
“The UK MOD and RAF are pleased with the progress of their MQ-9B PROTECTOR programme and work continues at pace on the certification aspects of this platform, ahead of achieving a full Military Type Certificate as the platform enters service. Recently-reported Protector procurement schedule adjustments reflect the UK government managing the transition between getting the most out of our current Reaper aircraft, which is helping us defeat Daesh in the Middle East, and moving to the cutting-edge Protector,” said Air Marshal Julian Young, Chief of Materiel (Air) at DE&S. “The Protector programme, which is based on GA-ASI’s SkyGuardian aircraft, is a key capability for the UK, and the MOD and GA-ASI have worked collaboratively to support programme changes, as well as continuing to meet growing interest in this unique capability.”
Hi-resolution photos of MQ-9B are available to qualified media outlets from the listed GA-ASI media contact.
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable Unmanned Aircraft Systems (UAS), radars, and electro-optic and related mission systems, including the Predator®, Reaper® and Gray Eagle UAS programs of record and the Lynx® Multi-mode Radar. Celebrating over 25 years of aviation innovation, GA-ASI provides long-endurance, multi-mission capable aircraft with integrated sensor and data link systems required to deliver persistent flight, enabling situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.
Predator, Reaper, and Lynx are registered trademarks and SkyGuardian is a trademark of General Atomics Aeronautical Systems, Inc.
General Atomics Aeronautical Systems, Inc.
+1 (858) 524-8108
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00 | Tiedote
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme